{"hands_on_practices": [{"introduction": "The effect of a genetic mutation on drug-target interaction often begins with a change in the binding energetics. This exercise explores the fundamental thermodynamic relationship between the standard Gibbs free energy of binding, $\\Delta G^{\\circ}$, and the dissociation constant, $K_d$. By working through this problem, you will derive how a mutation-induced change in binding energy, $\\Delta\\Delta G$, directly translates into a quantifiable fold-change in binding affinity, a critical first step in predicting a variant's clinical significance [@problem_id:4953009].", "problem": "A small molecule inhibitor binds to the wild-type catalytic domain of a protein kinase with a dissociation constant $\\;K_{d}\\;$ defined by the thermodynamic relationship between the standard Gibbs free energy of binding $\\;\\Delta G^{\\circ}\\;$ and the dissociation constant. A single amino acid substitution in the drug target changes the binding free energy by $\\;\\Delta\\Delta G\\;$ relative to wild-type, where $\\;\\Delta\\Delta G = \\Delta G^{\\circ}_{\\text{mut}} - \\Delta G^{\\circ}_{\\text{wt}}\\;$ and $\\;\\Delta G^{\\circ}_{\\text{wt}}\\;$ and $\\;\\Delta G^{\\circ}_{\\text{mut}}\\;$ are the standard Gibbs free energies of binding for wild-type and mutant, respectively. Starting from the fundamental thermodynamic relationship between standard Gibbs free energy and equilibrium constants, and the definition of $\\;\\Delta\\Delta G\\;$, derive a general expression for the fold-change in dissociation constant $\\;K_{d}'/K_{d}\\;$ caused by the mutation, where $\\;K_{d}'\\;$ is the mutant dissociation constant. Then evaluate this fold-change for $\\;\\Delta\\Delta G = 1.4\\;\\text{kcal}\\cdot\\text{mol}^{-1}\\;$ at temperature $\\;T = 298\\;\\text{K}\\;$ using the universal gas constant $\\;R = 1.987 \\times 10^{-3}\\;\\text{kcal}\\cdot\\text{mol}^{-1}\\cdot\\text{K}^{-1}\\;$. Express the final fold-change as a unitless number and round your answer to three significant figures.", "solution": "The problem is validated by following the specified procedure.\n\n### Step 1: Extract Givens\n- Wild-type dissociation constant: $K_d$\n- Mutant dissociation constant: $K_d'$\n- Standard Gibbs free energy of binding for wild-type: $\\Delta G^{\\circ}_{\\text{wt}}$\n- Standard Gibbs free energy of binding for mutant: $\\Delta G^{\\circ}_{\\text{mut}}$\n- Change in standard Gibbs free energy of binding due to mutation: $\\Delta\\Delta G = \\Delta G^{\\circ}_{\\text{mut}} - \\Delta G^{\\circ}_{\\text{wt}}$\n- Value of the change in free energy: $\\Delta\\Delta G = 1.4\\;\\text{kcal}\\cdot\\text{mol}^{-1}$\n- Temperature: $T = 298\\;\\text{K}$\n- Universal gas constant: $R = 1.987 \\times 10^{-3}\\;\\text{kcal}\\cdot\\text{mol}^{-1}\\cdot\\text{K}^{-1}$\n- Required output: A general expression for the fold-change $K_{d}'/K_{d}$, and its numerical value rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded:** The problem is based on the fundamental thermodynamic relationship between the standard Gibbs free energy change ($\\Delta G^{\\circ}$) and the equilibrium constant ($K_{\\text{eq}}$) of a reaction, specifically applied to protein-ligand binding. The concepts of dissociation constants ($K_d$) and the differential free energy change upon mutation ($\\Delta\\Delta G$) are standard and central to biophysical chemistry and pharmacology. The problem is scientifically sound.\n- **Well-Posed:** The problem provides a clear objective: derive a relationship and then evaluate it numerically. All necessary constants and variables ($R$, $T$, $\\Delta\\Delta G$) are provided with consistent units. The problem is self-contained and leads to a unique, meaningful solution.\n- **Objective:** The problem is stated using precise, unbiased scientific terminology. No subjective claims are made.\n\n### Step 3: Verdict and Action\nThe problem is valid as it is scientifically grounded, well-posed, objective, and contains no discernible flaws. The solution will proceed.\n\nThe fundamental thermodynamic relationship connects the standard Gibbs free energy change of a reaction, $\\Delta G^{\\circ}$, to its equilibrium constant, $K_{\\text{eq}}$, via the equation:\n$$ \\Delta G^{\\circ} = -RT \\ln K_{\\text{eq}} $$\nwhere $R$ is the universal gas constant and $T$ is the absolute temperature.\n\nFor the binding of a ligand ($L$) to a protein ($P$), the association reaction is $P + L \\rightleftharpoons PL$. The equilibrium constant for this reaction is the association constant, $K_a = \\frac{[PL]}{[P][L]}$.\nThe dissociation constant, $K_d$, corresponds to the reverse reaction, $PL \\rightleftharpoons P + L$, and is the reciprocal of the association constant: $K_d = \\frac{1}{K_a}$.\n\nThe problem refers to the \"standard Gibbs free energy of binding\", which conventionally corresponds to the association process. Let this be $\\Delta G^{\\circ}_{\\text{bind}}$. Thus,\n$$ \\Delta G^{\\circ}_{\\text{bind}} = -RT \\ln K_a $$\nSubstituting $K_a = 1/K_d$ into this equation gives the relationship in terms of the dissociation constant:\n$$ \\Delta G^{\\circ}_{\\text{bind}} = -RT \\ln\\left(\\frac{1}{K_d}\\right) = -RT(-\\ln K_d) = RT \\ln K_d $$\nThis equation relates the standard Gibbs free energy of binding to the dissociation constant $K_d$.\n\nWe can write this relationship for both the wild-type (wt) and mutant (mut) proteins:\n1. For the wild-type protein, with dissociation constant $K_d$ and standard Gibbs free energy of binding $\\Delta G^{\\circ}_{\\text{wt}}$:\n$$ \\Delta G^{\\circ}_{\\text{wt}} = RT \\ln K_d $$\n2. For the mutant protein, with dissociation constant $K_d'$ and standard Gibbs free energy of binding $\\Delta G^{\\circ}_{\\text{mut}}$:\n$$ \\Delta G^{\\circ}_{\\text{mut}} = RT \\ln K_d' $$\nThe problem defines the change in binding free energy due to the mutation as $\\Delta\\Delta G$:\n$$ \\Delta\\Delta G = \\Delta G^{\\circ}_{\\text{mut}} - \\Delta G^{\\circ}_{\\text{wt}} $$\nSubstituting the expressions for $\\Delta G^{\\circ}_{\\text{mut}}$ and $\\Delta G^{\\circ}_{\\text{wt}}$ into this definition:\n$$ \\Delta\\Delta G = (RT \\ln K_d') - (RT \\ln K_d) $$\nFactoring out the common term $RT$:\n$$ \\Delta\\Delta G = RT (\\ln K_d' - \\ln K_d) $$\nUsing the logarithmic identity $\\ln a - \\ln b = \\ln(a/b)$, we combine the logarithmic terms:\n$$ \\Delta\\Delta G = RT \\ln\\left(\\frac{K_d'}{K_d}\\right) $$\nTo derive the general expression for the fold-change in the dissociation constant, $K_d'/K_d$, we rearrange this equation. First, divide by $RT$:\n$$ \\frac{\\Delta\\Delta G}{RT} = \\ln\\left(\\frac{K_d'}{K_d}\\right) $$\nThen, exponentiate both sides with base $e$ to eliminate the natural logarithm:\n$$ \\frac{K_d'}{K_d} = \\exp\\left(\\frac{\\Delta\\Delta G}{RT}\\right) $$\nThis is the general expression for the fold-change in dissociation constant as a function of the change in binding free energy.\n\nNext, we evaluate this expression using the provided numerical values:\n- $\\Delta\\Delta G = 1.4\\;\\text{kcal}\\cdot\\text{mol}^{-1}$\n- $T = 298\\;\\text{K}$\n- $R = 1.987 \\times 10^{-3}\\;\\text{kcal}\\cdot\\text{mol}^{-1}\\cdot\\text{K}^{-1}$\n\nFirst, we calculate the dimensionless exponent $\\frac{\\Delta\\Delta G}{RT}$:\n$$ \\frac{\\Delta\\Delta G}{RT} = \\frac{1.4\\;\\text{kcal}\\cdot\\text{mol}^{-1}}{(1.987 \\times 10^{-3}\\;\\text{kcal}\\cdot\\text{mol}^{-1}\\cdot\\text{K}^{-1}) \\times (298\\;\\text{K})} $$\nThe units cancel out as expected: $\\frac{\\text{kcal}\\cdot\\text{mol}^{-1}}{(\\text{kcal}\\cdot\\text{mol}^{-1}\\cdot\\text{K}^{-1}) \\cdot \\text{K}}$.\n$$ \\frac{\\Delta\\Delta G}{RT} = \\frac{1.4}{0.592126} \\approx 2.36437 $$\nNow, we calculate the fold-change:\n$$ \\frac{K_d'}{K_d} = \\exp(2.36437) \\approx 10.63806 $$\nThe problem requires the answer to be rounded to three significant figures.\n$$ \\frac{K_d'}{K_d} \\approx 10.6 $$\nA positive $\\Delta\\Delta G$ of $1.4\\;\\text{kcal}\\cdot\\text{mol}^{-1}$ indicates that the mutation is unfavorable for binding, weakening the affinity. This corresponds to an increase in the dissociation constant, so a fold-change greater than $1$ is expected, consistent with our result.", "answer": "$$\\boxed{10.6}$$", "id": "4953009"}, {"introduction": "A change in a drug's binding affinity, quantified by the dissociation constant $K_d$, directly impacts its ability to occupy its target at a given concentration. This exercise applies the classic one-site binding model to translate a known shift in $K_d$ into a change in receptor fractional occupancy. This practice is key to understanding how a genetic variation can lead to a reduced drug effect even when drug concentrations in the body are normal [@problem_id:4953022].", "problem": "A small molecule inhibitor is developed to bind a single active site on a receptor tyrosine kinase. Binding is reversible and occurs at one site per receptor molecule, with no cooperativity and no competing ligands. Assume the system is at thermodynamic equilibrium and follows the law of mass action. The drugâ€“receptor binding is characterized by an equilibrium dissociation constant ($K_d$), defined by the ratio of the product of free concentrations to the complex concentration at equilibrium. A clinically observed single-nucleotide polymorphism (SNP) in the target protein changes the equilibrium dissociation constant from $K_{d,\\mathrm{WT}} = 4\\,\\mathrm{nM}$ in the wild-type to $K_{d,\\mathrm{mut}} = 40\\,\\mathrm{nM}$ in the mutant. The free drug concentration at the site of action is maintained at a fixed value of $[D] = 12\\,\\mathrm{nM}$.\n\nUsing only first principles of reversible one-site binding at equilibrium, compute the fold-change in receptor fractional occupancy due to the mutation at the fixed drug concentration, defined as the ratio of mutant occupancy to wild-type occupancy. Express the fold-change as a decimal fraction, and round your final answer to three significant figures. No units should be included in the final fold-change.", "solution": "The problem will be validated against the specified criteria before a solution is attempted.\n\n### Step 1: Extract Givens\n- The system involves a small molecule inhibitor (drug, D) binding to a single active site on a receptor tyrosine kinase (R).\n- Binding is reversible: $R + D \\rightleftharpoons RD$.\n- Binding occurs at one site per receptor molecule.\n- There is no cooperativity.\n- There are no competing ligands.\n- The system is at thermodynamic equilibrium.\n- The system follows the law of mass action.\n- The equilibrium dissociation constant ($K_d$) is defined as $K_d = \\frac{[R][D]}{[RD]}$, where $[R]$ is the free receptor concentration, $[D]$ is the free drug concentration, and $[RD]$ is the drug-receptor complex concentration.\n- Wild-type equilibrium dissociation constant: $K_{d,\\mathrm{WT}} = 4\\,\\mathrm{nM}$.\n- Mutant equilibrium dissociation constant: $K_{d,\\mathrm{mut}} = 40\\,\\mathrm{nM}$.\n- Fixed free drug concentration: $[D] = 12\\,\\mathrm{nM}$.\n- The objective is to compute the fold-change in receptor fractional occupancy, defined as the ratio of mutant occupancy to wild-type occupancy: $\\frac{\\theta_{\\mathrm{mut}}}{\\theta_{\\mathrm{WT}}}$.\n- The final answer must be a decimal fraction rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated based on the provided criteria.\n- **Scientifically Grounded**: The problem describes a classic one-site, non-cooperative ligand-receptor binding model, which is a fundamental concept in pharmacology and biochemistry governed by the law of mass action. The equilibrium dissociation constant, $K_d$, is the standard metric for binding affinity. The scenario of a single-nucleotide polymorphism (SNP) altering $K_d$ is a well-established mechanism for genetic variation in drug response. The numerical values for $K_d$ and $[D]$ are chemically realistic. The problem is scientifically sound.\n- **Well-Posed**: The problem provides all necessary parameters ($K_{d,\\mathrm{WT}}$, $K_{d,\\mathrm{mut}}$, and $[D]$) and a clear definition of the quantity to be calculated (fold-change in fractional occupancy). A unique, stable, and meaningful solution can be determined.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language.\n\n### Step 3: Verdict and Action\nThe problem is scientifically grounded, well-posed, objective, and self-contained. It is deemed **valid**. A solution will be derived from first principles.\n\n### Solution Derivation\nThe problem requires the derivation of the fractional occupancy of the receptor from first principles. The binding reaction is given by:\n$$ R + D \\rightleftharpoons RD $$\nwhere $R$ represents the free receptor, $D$ the free drug, and $RD$ the drug-receptor complex.\n\nAccording to the law of mass action, at equilibrium, the rates of association and dissociation are equal. The equilibrium dissociation constant, $K_d$, is defined as:\n$$ K_d = \\frac{[R][D]}{[RD]} $$\nwhere $[R]$, $[D]$, and $[RD]$ are the molar concentrations of the free receptor, free drug, and complex at equilibrium, respectively.\n\nThe total concentration of receptors, $[R]_T$, is the sum of the free and bound receptors:\n$$ [R]_T = [R] + [RD] $$\nThe fractional occupancy, $\\theta$, is defined as the fraction of the total receptors that are in the bound state:\n$$ \\theta = \\frac{[RD]}{[R]_T} = \\frac{[RD]}{[R] + [RD]} $$\nTo express $\\theta$ in terms of the known quantities $[D]$ and $K_d$, we first rearrange the $K_d$ expression to solve for $[R]$:\n$$ [R] = \\frac{K_d [RD]}{[D]} $$\nNow, we substitute this expression for $[R]$ into the denominator of the equation for $\\theta$:\n$$ \\theta = \\frac{[RD]}{\\frac{K_d [RD]}{[D]} + [RD]} $$\nFactoring out $[RD]$ from the denominator yields:\n$$ \\theta = \\frac{[RD]}{[RD] \\left( \\frac{K_d}{[D]} + 1 \\right)} $$\nAssuming $[RD]$ is not zero, it can be canceled from the numerator and denominator:\n$$ \\theta = \\frac{1}{1 + \\frac{K_d}{[D]}} $$\nMultiplying the numerator and denominator by $[D]$ gives the standard form of the Hill-Langmuir equation for single-site binding:\n$$ \\theta = \\frac{[D]}{[D] + K_d} $$\nThis equation relates the fractional occupancy $\\theta$ to the free drug concentration $[D]$ and the equilibrium dissociation constant $K_d$.\n\nWe can now apply this equation to both the wild-type (WT) and mutant (mut) receptors. The free drug concentration $[D]$ is constant for both cases.\n\nFor the wild-type receptor:\n$$ \\theta_{\\mathrm{WT}} = \\frac{[D]}{[D] + K_{d,\\mathrm{WT}}} $$\nFor the mutant receptor:\n$$ \\theta_{\\mathrm{mut}} = \\frac{[D]}{[D] + K_{d,\\mathrm{mut}}} $$\nThe problem asks for the fold-change in occupancy, defined as the ratio $\\frac{\\theta_{\\mathrm{mut}}}{\\theta_{\\mathrm{WT}}}$.\n$$ \\text{Fold-change} = \\frac{\\theta_{\\mathrm{mut}}}{\\theta_{\\mathrm{WT}}} = \\frac{\\frac{[D]}{[D] + K_{d,\\mathrm{mut}}}}{\\frac{[D]}{[D] + K_{d,\\mathrm{WT}}}} $$\nSimplifying this complex fraction gives:\n$$ \\text{Fold-change} = \\frac{[D]}{[D] + K_{d,\\mathrm{mut}}} \\cdot \\frac{[D] + K_{d,\\mathrm{WT}}}{[D]} = \\frac{[D] + K_{d,\\mathrm{WT}}}{[D] + K_{d,\\mathrm{mut}}} $$\nNow, we substitute the given numerical values into this expression:\n- $[D] = 12\\,\\mathrm{nM}$\n- $K_{d,\\mathrm{WT}} = 4\\,\\mathrm{nM}$\n- $K_{d,\\mathrm{mut}} = 40\\,\\mathrm{nM}$\n\nThe units ($\\mathrm{nM}$) are consistent and will cancel, yielding a dimensionless ratio.\n$$ \\text{Fold-change} = \\frac{12 + 4}{12 + 40} = \\frac{16}{52} $$\nThis fraction can be simplified by dividing the numerator and denominator by their greatest common divisor, which is $4$:\n$$ \\text{Fold-change} = \\frac{16 \\div 4}{52 \\div 4} = \\frac{4}{13} $$\nTo express this as a decimal fraction, we perform the division:\n$$ \\frac{4}{13} \\approx 0.3076923... $$\nThe problem requires the answer to be rounded to three significant figures.\n$$ \\text{Fold-change} \\approx 0.308 $$\nThis result indicates that, at a drug concentration of $12\\,\\mathrm{nM}$, the mutation reduces the fractional occupancy of the receptor to approximately $30.8\\%$ of the wild-type occupancy. This is expected, as the mutation increased the $K_d$, signifying weaker binding affinity.", "answer": "$$ \\boxed{0.308} $$", "id": "4953022"}, {"introduction": "The ultimate goal of pharmacogenomics is to guide clinical decision-making, such as personalizing drug dosage. This practice synthesizes concepts of binding affinity and target occupancy to build a rational dose-adjustment algorithm. By deriving and applying a formula that links dose to the dissociation constant, you will see how to calculate a new dose for a patient with a genetic variant to achieve the same target engagement as a patient with the reference genotype, providing a clear example of model-informed precision dosing [@problem_id:4953011].", "problem": "A small-molecule inhibitor binds a receptor target via reversible binding that obeys the law of mass action. The clinically relevant pharmacodynamic objective is to maintain a fixed fraction of occupied target sites, denoted by $f^{\\ast}$, across patient genotypes. Assume the following fundamentals: the binding is characterized by a dissociation constant $K_{d}$, the total target concentration is constant, and the pharmacokinetics are linear. Specifically, under linear pharmacokinetics, the steady-state unbound drug concentration at the target site, denoted $C_{u}$, is proportional to the administered dose $D$ with a genotype-independent proportionality constant $k$, so that $C_{u} = kD$.\n\nIn a reference genotype (genotype A), the dissociation constant is $K_{d,A} = 4.0$ nM. In a variant genotype (genotype B) with a missense substitution in the drug-binding pocket, the dissociation constant is $K_{d,B} = 9.2$ nM. In genotype A, a once-daily oral dose of $D_{A} = 95$ mg achieves the desired target engagement $f^{\\ast}$ at steady state. Assume the variant genotype does not change absorption, clearance, distribution, or $k$.\n\nConstruct an algorithm that adjusts the dose to preserve $f^{\\ast}$ when $K_{d}$ shifts due to genotype and, using this algorithm, compute the revised once-daily dose $D_{B}$ for genotype B that maintains the same $f^{\\ast}$. Round your answer to four significant figures and express the dose in mg.", "solution": "The problem requires the construction of an algorithm to adjust a drug dose to maintain a constant fraction of target receptor occupancy, $f^{\\ast}$, across different patient genotypes that affect the drug-target dissociation constant, $K_d$. This algorithm will then be used to calculate a specific new dose.\n\nFirst, let us formalize the relationship between target occupancy, drug concentration, and the dissociation constant. The binding of a small-molecule inhibitor (drug, $L$) to its receptor target ($R$) is described by the reversible reaction:\n$$ R + L \\rightleftharpoons RL $$\nwhere $RL$ is the drug-receptor complex. According to the law of mass action, the dissociation constant, $K_d$, is defined as:\n$$ K_d = \\frac{[R][L]}{[RL]} $$\nwhere $[R]$, $[L]$, and $[RL]$ are the molar concentrations of the free receptor, free drug, and the complex at equilibrium, respectively. The unbound drug concentration at the target site is given as $C_u$, so $[L] = C_u$.\n\nThe total concentration of the receptor, $[R]_T$, is the sum of the free and bound receptor concentrations:\n$$ [R]_T = [R] + [RL] $$\nThe fraction of occupied target sites, $f$, is the ratio of the concentration of the bound receptor to the total receptor concentration:\n$$ f = \\frac{[RL]}{[R]_T} $$\nWe can express $f$ in terms of $C_u$ and $K_d$. From the definition of $[R]_T$, we have $[R] = [R]_T - [RL]$. Substituting this into the expression for $K_d$:\n$$ K_d = \\frac{([R]_T - [RL])C_u}{[RL]} $$\nRearranging this equation to solve for the fractional occupancy $f$:\n$$ K_d [RL] = ([R]_T - [RL])C_u = [R]_T C_u - [RL] C_u $$\n$$ [RL](K_d + C_u) = [R]_T C_u $$\n$$ f = \\frac{[RL]}{[R]_T} = \\frac{C_u}{K_d + C_u} $$\nThis is the Hill-Langmuir equation, which represents the fundamental relationship for this problem.\n\nThe pharmacodynamic objective is to maintain a constant fractional occupancy, $f = f^{\\ast}$, for all genotypes. To construct the dose-adjustment algorithm, we analyze this condition. If $f$ is constant, then the expression $\\frac{C_u}{K_d + C_u}$ must be constant. Let's solve this for $C_u$:\n$$ f^{\\ast} (K_d + C_u) = C_u $$\n$$ f^{\\ast} K_d + f^{\\ast} C_u = C_u $$\n$$ f^{\\ast} K_d = C_u (1 - f^{\\ast}) $$\n$$ C_u = K_d \\left( \\frac{f^{\\ast}}{1 - f^{\\ast}} \\right) $$\nSince $f^{\\ast}$ is a constant, the term in the parenthesis, $\\frac{f^{\\ast}}{1 - f^{\\ast}}$, is also a constant. This implies that to maintain constant target occupancy, the unbound drug concentration $C_u$ must be directly proportional to the dissociation constant $K_d$.\n\nLet's apply this finding to the two genotypes, A (reference) and B (variant). To maintain $f^{\\ast}$, the following must hold:\n$$ \\frac{C_{u,A}}{K_{d,A}} = \\frac{f^{\\ast}}{1 - f^{\\ast}} $$\n$$ \\frac{C_{u,B}}{K_{d,B}} = \\frac{f^{\\ast}}{1 - f^{\\ast}} $$\nTherefore, the condition for maintaining constant occupancy across genotypes is:\n$$ \\frac{C_{u,A}}{K_{d,A}} = \\frac{C_{u,B}}{K_{d,B}} $$\n\nThe problem states that the pharmacokinetics are linear, such that the steady-state unbound drug concentration $C_u$ is proportional to the dose $D$ via a constant $k$:\n$$ C_u = k D $$\nThe constant of proportionality $k$ is specified to be independent of genotype. Substituting this relationship into our condition:\n$$ \\frac{k D_A}{K_{d,A}} = \\frac{k D_B}{K_{d,B}} $$\nSince $k$ is a non-zero constant, it can be cancelled from both sides of the equation:\n$$ \\frac{D_A}{K_{d,A}} = \\frac{D_B}{K_{d,B}} $$\n\nThis equation represents the algorithm for dose adjustment. To find the revised dose $D_B$ for genotype B that preserves the target occupancy $f^{\\ast}$ achieved with dose $D_A$ in genotype A, we rearrange the equation:\n$$ D_B = D_A \\left( \\frac{K_{d,B}}{K_{d,A}} \\right) $$\nThis algorithm states that the dose must be adjusted in direct proportion to the change in the dissociation constant. A weaker binding affinity (higher $K_d$) requires a proportionally higher dose to achieve the same level of target engagement.\n\nNow, we apply this algorithm using the provided data:\n-   Dose for genotype A, $D_A = 95$ mg.\n-   Dissociation constant for genotype A, $K_{d,A} = 4.0$ nM.\n-   Dissociation constant for genotype B, $K_{d,B} = 9.2$ nM.\n\nSubstituting these values into our derived formula for $D_B$:\n$$ D_B = 95 \\, \\text{mg} \\times \\left( \\frac{9.2 \\, \\text{nM}}{4.0 \\, \\text{nM}} \\right) $$\nThe units of nM cancel out, as expected.\n$$ D_B = 95 \\times \\frac{9.2}{4.0} $$\n$$ D_B = 95 \\times 2.3 $$\n$$ D_B = 218.5 \\, \\text{mg} $$\n\nThe problem requests the answer to be rounded to four significant figures. The calculated value of $218.5$ has exactly four significant figures, so no further rounding is necessary. The required once-daily dose for an individual with genotype B is $218.5$ mg.", "answer": "$$\n\\boxed{218.5}\n$$", "id": "4953011"}]}